Anthony G. Quinn's Net Worth
$6.19 Million
Who is Anthony G. Quinn?
Anthony G. Quinn has an estimated net worth of $6.19 Million. This is based on reported shares across multiple companies, which include Kaleido Biosciences, Inc., Generation Bio Co., Aeglea BioTherapeutics, Inc., and SYNAGEVA BIOPHARMA CORP.
SEC CIK
Anthony G. Quinn's CIK is 0001532219
Past Insider Trading and Trends
2019 was Anthony G. Quinn's most active year for acquiring shares with 16 total transactions. Anthony G. Quinn's most active month to acquire stocks was the month of May. 2015 was Anthony G. Quinn's most active year for disposing of shares, totalling 17 transactions. Anthony G. Quinn's most active month to dispose stocks was the month of March. 2020 saw Anthony G. Quinn paying a total of $783,750.00 for 563,376 shares, this is the most they've acquired in one year. In 2015 Anthony G. Quinn cashed out on 329,352 shares for a total of $5,996,201.28, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Kaleido Biosciences, Inc. (KLDO) Snapshot price: $0.000001
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
| +68.55% | 12.85K |
—
|
—
| 31.6K |
Mar 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Generation Bio Co. (GBIO) Snapshot price: $1.87
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 88.5K |
$1.41 | $124,777.95 | 88.5K |
Dec 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
| 72.84K |
Oct 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
| +71.54% | 30.38K |
—
|
—
| 72.84K |
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aeglea BioTherapeutics, Inc. (AGLE) No price found
President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +17.02% | 80.08K |
$2.34 | $187,705.18 | 550.54K |
Mar 16
| |||
Form 4
| +44.00% | 144.67K |
$1.94 | $280,942.97 | 473.46K |
Mar 11 - Mar 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 17
| |||
Form 4
| +19.49% | 53.63K |
$3.71 | $198,972.10 | 328.8K |
Dec 9 - Dec 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 17
| |||
Form 4
| +44.18% | 165K |
$4.75 | $783,750.00 | 538.47K |
Apr 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
| +5.16% | 18.27K |
$6.28 | $114,689.45 | 371.91K |
Oct 4
| |||
Form 4
| +9.92% | 31.91K |
$6.16 | $196,453.22 | 353.64K |
Jun 12 - Jun 14
| |||
Form 4
| +9.01% | 26.59K |
$6.77 | $180,032.46 | 321.74K |
May 20 - May 22
| |||
Form 4
| +6.77% | 18.71K |
$6.75 | $126,398.71 | 295.15K |
Feb 15 - May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 28
| |||
Form 4
| +3.27% | 8.76K |
$6.18 | $54,125.81 | 276.43K |
Feb 6
| |||
Form 4
| +188.47% | 174.88K |
$4.42 | $772,931.02 | 267.68K |
Feb 15 - Dec 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 18
| |||
Form 4
| +72.07% | 38.87K |
$6.76 | $262,764.46 | 92.79K |
Jul 12
| |||
Form 4
| +6.53% | 3.31K |
$5.46 | $18,056.22 | 53.93K |
Jul 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 20
| |||
Form 4
| +42.96% | 15.21K |
$5.46 | $83,052.06 | 50.62K |
Feb 15
| |||
Form 4
| +30.56% | 8.29K |
$4.96 | $41,078.38 | 35.41K |
Dec 6 - Dec 8
| |||
Form 4
| +171.21% | 17.12K |
$4.86 | $83,177.50 | 27.12K |
Dec 1 - Dec 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 21
| |||
Form 4
|
∞
| 10K |
$10.00 | $100,000.00 | 10K |
Apr 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
SYNAGEVA BIOPHARMA CORP No price found
EVP, CMO, & Head R&D
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -32.64K |
$78.87 | $2,997.06 |
0
|
Jun 22
| |||
Form 4
| +478.98% | 27K |
—
|
—
| 32.64K |
Jun 5
| |||
Form 4
|
—
|
0
|
$55.85 | -$1,083,000.00 | 5.64K |
Scheduled
|
Apr 27
| ||
Form 4
| -63.95% | -10.00K |
$108.00 | -$1,080,000.00 | 5.64K |
Scheduled
|
Apr 21
| ||
Form 4
|
—
|
0
|
$72.87 | -$642,600.00 | 15.64K |
Scheduled
|
Apr 15
| ||
Form 4
| -38.91% | -9.96K |
$52.80 | -$2,534,903.32 | 15.64K |
Scheduled
|
Apr 6
| ||
Form 4
|
—
|
0
|
$46.57 | -$471,404.00 | 25.59K |
Scheduled
|
Sep 2
| ||
Form 4
| +0.28% | 71 |
$54.89 | $3,897.19 | 25.59K |
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
| +64.42% | 10K |
$0.95 | $9,500.00 | 25.52K |
Scheduled
|
Apr 1
| ||
Form 4
|
—
|
0
|
$47.76 | -$1,431,190.62 | 15.52K |
Scheduled
|
Apr 1
| ||
Form 4
| +1.25% | 192 |
$36.30 | $6,969.60 | 15.52K |
Dec 31
| |||
Form 4
| +1.98% | 297 |
$35.68 | $10,596.96 | 15.33K |
Jun 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
$25.52 | -$464,131.11 | 15.04K |
Scheduled
|
Jan 18
| ||
Form 4
| -24.96% | -5.00K |
$25.51 | -$277,499.36 | 15.04K |
Scheduled
|
Jan 16 - Jan 17
| ||
Form 4
|
—
|
0
|
$25.58 | -$369,376.44 | 20.04K |
Scheduled
|
Jul 26 - Jul 27
| ||
Form 4
|
—
|
0
|
$25.48 | -$122,625.00 | 20.04K |
Scheduled
|
Jul 19 - Jul 20
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 27
| |||
Form 4
| -56.48% | -26.00K |
$40.65 | -$1,056,874.00 | 20.04K |
Scheduled
|
Jun 25
| ||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Dec 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||